For studies that reported on adverse events at multiple time points — we extracted data for the longest point of follow-up that included, at minimum, 80% of the patients recruited into the study. We report our systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Harms Checklist.22 We found insufficient evidence addressing the harms of medical cannabis compared with other pain management options, such as opioids.
This difference (however), is considered barely clinically significant.25,26 The classification of pain dictates that we approach the question of beneficial effects by subgrouping pain into various types. Unfortunately, MMJ is also similar to opioids in that robust data establishing long-term benefit for chronic pain are scarce. To think medical and recreational use of marijuana do not considerably overlap would be naive — and we should avoid taking the same path we took with opioids.
There is one product where it makes me more active… but then I’m hurting because I’ve overdone it and been moving all day. It is making a difference but not that much of one. ” 72 years, male The drops worked better, but I’m still trying to figure out what works for me. ” 61, male
Products with a higher percentage of THC are generally considered more effective for pain relief but carry a higher risk for psychotomimetic side effects. Unlike THC (CBD is not psychotomimetic), so it does not give the “high” and it can https://audiokushhq.com/cannabis-at-music-events-rules-and-realities/ help reduce THC’s psychotomimetic properties when used in combination. “But the clinical evidence is weaker — in large part due to low quality studies with low sample size or short duration of treatment and sometimes patient population not well-defined.” Overall, these studies suggest that prenatal exposure to CBD is likely to alter the production of testosterone, the function of the male gonads, and the receptor ligand interactions in the brain of offsprings. In addition, these reports conclude that chronic pain costs between $560 and $635 billion annually in both medical expenses and lost productivity.
1. Study Design and Population
Peripheral CB2 mechanisms in arthritic joints additionally illustrate how local immune modulation feeds back on central gain , Figure 5,. Postsynaptic anandamide release modulates presynaptic CB1/TRPV1 — leading to depressed transmitter release and neural circuit polarization underlying central sensitization. These forms of plasticity, classically observed as depolarization-induced suppression of inhibition or excitation, are prominent in spinal and cortical pain circuits . Δ9-tetrahydrocannabinol (THC) binds to CB1 receptors on presynaptic neurons (resulting in inhibition of excitatory neurotransmitter release), and to CB2 receptors on macrophages, leading to reduced production of proinflammatory cytokines.
Between 50 and 116 million adults in the United States are affected by chronic pain, a shocking statistic that exceeds the combined number of individuals impacted by heart disease, cancer, and diabetes (Committee on Advancing Pain Research Care and Education, 2011; Nahin, 2015; NIH, 2020). If further clinical research can yield a new category of drugs to enhance current painkillers or medications that address pain alongside nausea or loss of appetite, it seems well worth the effort to pursue. For this reason (it is recommended by the IOM team that clinical studies on cannabinoid medications be conducted), focusing on cancer patients undergoing chemotherapy and AIDS patients dealing with significant pain or wasting.
During the 1800s, researchers in Europe and the U.S. published over 100 studies on medical cannabis.7 Later, legal restrictions reduced its medical use. Overall (cannabinoids should be considered adjunctive rather than first-line therapy), reserved for carefully selected patients who do not achieve sufficient relief with standard treatments. The evidence does not confirm a superior short-term efficacy of opioids in neuropathic pain, which suggests a weaker comparative benefit overall 102,103. At the same time, a 2025 proposal introduced a new regulatory pathway for CBD products, aiming to reclassify certain CBD items under the Natural Health Products (NHPs) category, with requirements for strict labeling, licensing, and a THC cap of 0.001% 60,61.
The average age at which they first used was 34, while combined users had an average age of 23 and were more likely to be male. According to a recent survey of over 4,000 cannabis users in California, the primary reason people turn to cannabis for medical purposes is for pain relief, with those seeking assistance for sleep, anxiety, and stress following closely behind. Leafwell employs most of the researchers, assisting patients in obtaining medical marijuana cards in states where it is permitted.
Chandpur Govt. College